Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus.
about
Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial CulturesRespiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen.Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model.Identification of and human serum reactogenicity to neutralizing epitopes within the central unglycosylated region of the respiratory syncytial virus attachment protein.Primary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virus.Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies.Progress in the development of human parainfluenza virus vaccinesCurrent concepts and progress in RSV vaccine development.Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins.Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh.Progress in understanding and controlling respiratory syncytial virus: still crazy after all these yearsAntibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in miceCharacteristics of RSV-Specific Maternal Antibodies in Plasma of Hospitalized, Acute RSV Patients under Three Months of AgeSendai virus as a backbone for vaccines against RSV and other human paramyxovirusesAntibody response to respiratory syncytial virus infection in children <18 months oldTargeting RSV with vaccines and small molecule drugs.Vaccination against RSV: is maternal vaccination a good alternative to other approaches?Prospects for defined epitope vaccines for respiratory syncytial virus.Respiratory syncytial virus: current progress in vaccine development.Translational sciences approach to RSV vaccine development.Fc gamma receptors in respiratory syncytial virus infections: implications for innate immunity.Novel therapies and vaccines against the human respiratory syncytial virus.Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention.New Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV.Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis.The Human Immune Response to Respiratory Syncytial Virus Infection.Characterization of Pre-F-GCN4t, a Modified Human Respiratory Syncytial Virus Fusion Protein Stabilized in a Noncleaved Prefusion Conformation.IgG3 Snitcher of RSV Infections in the Very Young.A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age.Genetic variability in G2 and F2 region between biological clones of human respiratory syncytial virus with or without host immune selection pressureThe association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants.The Complexity of Antibody Responses Elicited against the Respiratory Syncytial Virus Glycoproteins in Hospitalized Children Younger than 2 Years.Prefusion F, postfusion F, G antibodies and disease severity in infants and young children with acute respiratory syncytial virus infection.Antibody response and avidity of respiratory syncytial virus-specific total IgG, IgG1, and IgG3 in young children.Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation.A viral-vectored RSV vaccine induces long-lived humoral immunity in cotton ratsProgress in respiratory virus vaccine development
P2860
Q28551477-DE4851CF-4F0D-473F-A8E6-2048C6698CF2Q30240274-710437DE-3A4E-4E94-97EC-A6A192BE427EQ33558475-65099C7A-4AF9-47E4-9D68-3B1A61789606Q33596700-038A0799-5BF2-4D31-8BEA-378D2469CE39Q33724997-743D6AE6-2036-4CB8-9AB5-90E983A42F26Q33768769-621A15ED-BB96-4FFD-B0DF-0B06C58CEB16Q33813095-1F5F20B7-A56C-46D1-A5C7-F081BF833745Q34193265-06B8447C-CA30-4186-8EE0-A5761BE0E384Q34209872-390607BA-F118-49BF-BEA4-C24114FA377FQ34396689-B937E700-25E5-4CCD-8663-C1BAA89D6ECAQ34457791-90DD1BF8-B645-4D13-8E0B-C88D2A8B1A67Q34504791-8BD55A73-3781-4916-A1F6-535A8CFD1B8EQ35102554-3FBA55A7-5219-41C6-B6A2-C046224E5575Q35566601-7AD657D5-A7CA-4762-8757-599FF1849EF7Q36106575-591239CF-BC15-4B16-A207-DE82E02E2799Q36263882-2402F9D8-82AE-40A2-8CB8-6B5801A255E5Q37118707-21261BA7-A9EE-49ED-A078-A759E2D279CEQ37135395-CBB6CF8A-5A50-4DB7-90E2-0C3AC4F30928Q37328584-F84A5C55-A461-4BF3-BF1A-917A8C172F47Q37514757-3F90ADD8-6345-4C33-9302-7CA8E0771F28Q37721415-A3CDBF3A-CC81-44E1-8BE9-B46F8273E1A0Q38079432-486AB529-C325-49E4-B8F0-23BB95DD25E0Q38140040-8C00607D-2F2B-4584-A931-590A61E9C057Q38162418-3F31EEDF-599D-4A30-9404-995514E1DBBBQ38604787-B26AAC44-B09F-4ED4-8753-83434896AF38Q38604949-BFFB1CF4-C53B-4661-9EA2-A85B966E2217Q38628928-158079C0-F5E4-4934-B6E9-9A3E5C93029EQ38660842-043270EC-D478-4554-B701-AC23877BD8B0Q39127064-C6956360-58D7-4692-B891-A933317CCD33Q40244825-1CD36834-47BC-4E05-A77C-3B5722A55515Q40346231-A7BC3765-0C20-4B01-976D-4D4E4D6C69E1Q41060727-F0A72041-E482-48BD-8C0E-0D273C13BA59Q41448272-19B8E7BA-5DDC-4D47-8779-0665F33AE39DQ41956937-5CA3937E-9F12-4C0C-8204-E18D4BEE7A65Q45323691-739C6346-BED8-4B73-B074-A5A1A0E78C96Q45326381-5ACE5DC6-ACB6-4AE1-8DC0-0DB15591B96EQ45364177-96F12A1A-6363-4832-B822-17F4B8A2C03AQ49361412-6D30B68E-B0A8-4132-B39B-49404156206FQ56794662-E9E6BF2A-02C9-4D85-B36F-4988A3521737Q56894869-6D88D5A1-DAAF-4ED5-9DD4-7CB6EAAB706C
P2860
Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Young infants can develop prot ...... h respiratory syncytial virus.
@en
Young infants can develop prot ...... h respiratory syncytial virus.
@nl
type
label
Young infants can develop prot ...... h respiratory syncytial virus.
@en
Young infants can develop prot ...... h respiratory syncytial virus.
@nl
prefLabel
Young infants can develop prot ...... h respiratory syncytial virus.
@en
Young infants can develop prot ...... h respiratory syncytial virus.
@nl
P2093
P2860
P50
P356
P1476
Young infants can develop prot ...... h respiratory syncytial virus.
@en
P2093
Bhagvanji Thumar
Jana B Shaw
Joshua J Shinoff
Raymond Reid
P2860
P304
P356
10.1086/591460
P407
P577
2008-10-01T00:00:00Z